Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLTCVE:CZXTSE:FCRNYSE:USA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$6.00+4.0%$6.46$5.20▼$15.60$11.06M0.911,277 shs34,297 shsCZXCanada Zinc MetalsC$0.31+∞C$0.31C$0.22▼C$0.39C$51.69MN/A238,645 shs118,500 shsFCRFirst Capital RealtyC$0.00C$18.60▼C$22.79N/AN/A468,009 shs3.04 million shsUSALiberty All-Star Equity Fund$6.85+0.5%$6.60$5.64▼$7.49N/A1.11750,746 shs1.18 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics+3.99%+7.33%-2.28%-25.19%-59.01%CZXCanada Zinc Metals0.00%0.00%0.00%0.00%0.00%FCRFirst Capital Realty0.00%0.00%0.00%0.00%0.00%USALiberty All-Star Equity Fund-0.07%+2.70%+3.09%+3.40%+0.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBOLTBolt Biotherapeutics3.4954 of 5 stars3.23.00.00.03.33.31.3CZXCanada Zinc MetalsN/AN/AN/AN/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/AN/AN/AN/AN/AN/AUSALiberty All-Star Equity FundN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.33Hold$50.00733.33% UpsideCZXCanada Zinc Metals 0.00N/AN/AN/AFCRFirst Capital Realty 4.00Strong BuyN/AN/AUSALiberty All-Star Equity Fund 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest USA, BOLT, CZX, and FCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/13/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$25.00 ➝ $20.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.50N/AN/A$29.89 per share0.20CZXCanada Zinc MetalsN/AN/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/AN/AN/AN/AUSALiberty All-Star Equity FundN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$63.12M-$33.40N/AN/AN/AN/A-94.51%-59.07%8/12/2025 (Estimated)CZXCanada Zinc MetalsN/AN/A0.00∞N/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/A0.00N/AN/AN/AN/AN/AN/AUSALiberty All-Star Equity FundN/AN/A0.00∞N/AN/AN/AN/A8/27/2025 (Estimated)Latest USA, BOLT, CZX, and FCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025BOLTBolt Biotherapeutics-$6.80-$5.80+$1.00-$0.29$0.77 million$1.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/ACZXCanada Zinc MetalsN/AN/AN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/AN/AN/AUSALiberty All-Star Equity Fund$0.689.93%N/AN/AN/ALatest USA, BOLT, CZX, and FCR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/14/2025USALiberty All-Star Equity Fundquarterly$0.1510.7%4/17/20254/17/20256/2/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.483.133.13CZXCanada Zinc MetalsN/AN/AN/AFCRFirst Capital RealtyN/AN/AN/AUSALiberty All-Star Equity FundN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%CZXCanada Zinc MetalsN/AFCRFirst Capital RealtyN/AUSALiberty All-Star Equity Fund9.95%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics30.90%CZXCanada Zinc MetalsN/AFCRFirst Capital RealtyN/AUSALiberty All-Star Equity Fund0.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.33 millionNot OptionableCZXCanada Zinc Metals147,000166.73 millionN/ANot OptionableFCRFirst Capital RealtyN/AN/AN/ANot OptionableUSALiberty All-Star Equity FundN/AN/AN/ANot OptionableUSA, BOLT, CZX, and FCR HeadlinesRecent News About These CompaniesUSA: Losing Its Steam Due To Macro-Uncertainty (Rating Downgrade)June 23, 2025 | seekingalpha.comLiberty All-Star® Equity Fund April 2025 Monthly UpdateMay 15, 2025 | finance.yahoo.comUSA: A Historical Underperformer, But Value-Orientation Might Be AppealingMay 11, 2025 | seekingalpha.comLiberty All-Star® Equity Fund March 2025 Monthly UpdateApril 15, 2025 | prnewswire.comLiberty All-Star® Equity Fund Declares DistributionApril 7, 2025 | prnewswire.comLiberty All-Star® Equity Fund February 2025 Monthly UpdateMarch 14, 2025 | prnewswire.comUSA: Delivers A High Yield Without Sacrificing Tech ExposureFebruary 25, 2025 | seekingalpha.comLiberty All-Star® Equity Fund January 2025 Monthly UpdateFebruary 14, 2025 | prnewswire.comCTBC Bank Contributes $300,000 to Support LAEDC's Small Business Recovery Efforts Following Los Angeles WildfiresFebruary 13, 2025 | businesswire.comLiberty All Star Equity Closed FundFebruary 9, 2025 | uk.investing.com2 Bright Yields Up To 10%January 25, 2025 | seekingalpha.comUSA: Why I Just Doubled My PositionJanuary 16, 2025 | seekingalpha.comLiberty All-Star® Equity Fund December 2024 Monthly UpdateJanuary 14, 2025 | prnewswire.comLiberty All-Star® Equity Fund Declares DistributionJanuary 13, 2025 | prnewswire.comUSA: Better Alternatives Available (Downgrade)January 10, 2025 | seekingalpha.com(USA) Long Term Investment AnalysisJanuary 8, 2025 | news.stocktradersdaily.comNHow to Take Advantage of moves in (USA)December 28, 2024 | news.stocktradersdaily.comNLiberty All-Star® Equity Fund November 2024 Monthly UpdateDecember 13, 2024 | prnewswire.comF1 has ‘great future’ says outgoing Liberty Media CEO, doesn’t see any plan to sell seriesNovember 14, 2024 | nytimes.comLiberty All-Star® Equity Fund October 2024 Monthly UpdateNovember 14, 2024 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeThe Top 116 Small Businesses Americans Want to Fund With $10K [2025 Survey]By MarketBeat Staff | June 24, 2025View The Top 116 Small Businesses Americans Want to Fund With $10K [2025 Survey]USA, BOLT, CZX, and FCR Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$6.00 +0.23 (+3.99%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$5.84 -0.16 (-2.73%) As of 07/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Canada Zinc Metals CVE:CZXC$0.31 +0.31 (+∞) As of 05/4/2018Canada Zinc Metals Corp. explores for and evaluates mineral resource properties in Canada. The company primarily explores for zinc-lead-silver base metals deposits. Its flagship property is the Akie property that consists of 46 mineral claims, which cover approximately 116 square kilometers, located in the Paleozoic Selwyn Basin, British Columbia. The company was formerly known as Mantle Resources Inc. and changed its name to Canada Zinc Metals Corp. in September 2008. Canada Zinc Metals Corp. was incorporated in 1988 and is headquartered in Vancouver, Canada.First Capital Realty TSE:FCRLiberty All-Star Equity Fund NYSE:USA$6.84 +0.04 (+0.51%) Closing price 07/1/2025 03:59 PM EasternExtended Trading$6.84 0.00 (0.00%) As of 07/1/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Liberty All Star Equity Fund is a closed-ended equity mutual fund launched and managed by ALPS Advisers, Inc. The fund is co-managed by Aristotle Capital Management, LLC, Pzena Investment Management, LLC, Delaware Investments Fund Advisers, Sustainable Growth Advisers, LP, and TCW Investment Management Company. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating across diversified sectors. It primarily invests in value and growth stocks of large cap companies. The fund benchmarks the performance of its portfolio against the Lipper Large-Cap Core Mutual Fund Average, the Dow Jones Industrial Average, the NASDAQ Composite Index, and the S&P 500 Index. Liberty All Star Equity Fund was formed on October 31, 1986 and is domiciled in the United States. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.